187 related articles for article (PubMed ID: 23975664)
1. Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Stenholm L; Stoehlmacher-Williams J; Al-Batran SE; Heussen N; Akin S; Pauligk C; Lehmann S; Senff T; Hofheinz RD; Ehninger G; Kramer M; Goekkurt E
Ann Oncol; 2013 Oct; 24(10):2581-2588. PubMed ID: 23975664
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy.
Wu C; Li M; Hu C; Duan H
Cancer Chemother Pharmacol; 2014 Feb; 73(2):335-41. PubMed ID: 24288122
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Goekkurt E; Al-Batran SE; Mogck U; Pauligk C; Hartmann JT; Kramer M; Jaeger E; Ehninger G; Stoehlmacher J
Ann Oncol; 2009 Mar; 20(3):481-5. PubMed ID: 19074750
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
[TBL] [Abstract][Full Text] [Related]
5. Association between common genetic variants in pre-microRNAs and prognosis of advanced gastric cancer treated with chemotherapy.
Tahara T; Okubo M; Shibata T; Kawamura T; Sumi K; Ishizuka T; Nagasaka M; Nakagawa Y; Arisawa T; Ohmiya N; Hirata I
Anticancer Res; 2014 Sep; 34(9):5199-204. PubMed ID: 25202115
[TBL] [Abstract][Full Text] [Related]
6. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Lorenzen S; Thuss-Patience P; Al-Batran SE; Lordick F; Haller B; Schuster T; Pauligk C; Luley K; Bichev D; Schumacher G; Homann N
Ann Oncol; 2013 Aug; 24(8):2068-73. PubMed ID: 23592699
[TBL] [Abstract][Full Text] [Related]
7. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer.
Yoon KA; Yoon H; Park S; Jang HJ; Zo JI; Lee HS; Lee JS
J Thorac Cardiovasc Surg; 2012 Oct; 144(4):794-807. PubMed ID: 22818121
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
10. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thomaidis T; Maderer A; Al-Batran SE; Kany J; Pauligk C; Steinmetz K; Schad A; Hofheinz R; Schmalenberg H; Homann N; Galle PR; Moehler M
BMC Cancer; 2014 Jul; 14():476. PubMed ID: 24981311
[TBL] [Abstract][Full Text] [Related]
11. Association of the miR-146a rs2910164 polymorphism with gastric cancer susceptibility and prognosis.
Jiang J; Jia ZF; Cao DH; Wu YH; Sun ZW; Cao XY
Future Oncol; 2016 Oct; 12(19):2215-26. PubMed ID: 27267319
[TBL] [Abstract][Full Text] [Related]
12. Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.
Oh SY; Shin A; Kim SG; Hwang JA; Hong SH; Lee YS; Kwon HC
Oncotarget; 2016 May; 7(21):31204-14. PubMed ID: 27144430
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Kim YJ; Goh PG; Kim ES; Lee SY; Moon HS; Lee ES; Sung JK; Kim SH; Lee BS; Jeong HY
Korean J Gastroenterol; 2011 Dec; 58(6):311-7. PubMed ID: 22198228
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Rivera F; Massutí B; Salcedo M; Sastre J; Martínez Galán J; Valladares-Ayerbes M; Serrano R; García de Paredes ML; Manzano JL; Galán M; Alsina M; Yuste Izquierdo AL; López C; Díaz-Rubio E; Conde V; Reboredo M; Cano MT; Pachón V; Aranda E
Cancer Chemother Pharmacol; 2015 Feb; 75(2):319-24. PubMed ID: 25491381
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
Geng R; Chen Z; Zhao X; Qiu L; Liu X; Liu R; Guo W; He G; Li J; Zhu X
PLoS One; 2014; 9(12):e116027. PubMed ID: 25545243
[TBL] [Abstract][Full Text] [Related]
16. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Ji SH; Lim DH; Yi SY; Kim HS; Jun HJ; Kim KH; Chang MH; Park MJ; Uhm JE; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
BMC Cancer; 2009 Apr; 9():110. PubMed ID: 19358705
[TBL] [Abstract][Full Text] [Related]
18. MiR-196a2 rs11614913 T > C polymorphism and risk of esophageal cancer in a Chinese population.
Wei J; Zheng L; Liu S; Yin J; Wang L; Wang X; Shi Y; Shao A; Tang W; Ding G; Liu C; Chen S; Gu H
Hum Immunol; 2013 Sep; 74(9):1199-205. PubMed ID: 23792053
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
[TBL] [Abstract][Full Text] [Related]
20. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Kripp M; Al-Batran SE; Rosowski J; Pauligk C; Homann N; Hartmann JT; Moehler M; Hofheinz RD
Gastric Cancer; 2014 Jan; 17(1):181-7. PubMed ID: 23455717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]